Show
Sort by
-
- Journal Article
- open access
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease
-
- Journal Article
- A1
- open access
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression : results from the SORAYA study
-
Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23/KMT2A rearrangements in a modern therapy era : a retrospective international study
-
Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data
-
- Journal Article
- A1
- open access
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the International Berlin-Frankfurt-Münster Study Group
-
Reply to Z.R. McCaw et al
-
- Journal Article
- A1
- open access
Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer : placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial
-
- Journal Article
- A1
- open access
Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer : results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
-
- Journal Article
- A1
- open access
Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis
-
Short and medium-term outcomes of patients with solid cancer hospitalized with COVID-19 in Belgium according to cancer diagnosis and treatment characteristics
-
- Journal Article
- A1
- open access
Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial
-
- Journal Article
- A1
- open access
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials
-
Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT) : preliminary phase 1/2 results
-
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2, cohort B
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results
-
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) : phase 1/2 data update
-
- Journal Article
- A1
- open access
Combining Ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia : final analysis of the phase I/II HOVON124/ECWM-R2 study
-
- Journal Article
- A1
- open access
The critical role of academic clinical trials in pediatric cancer drug approvals : design, conduct, and fit for purpose data for positive regulatory decisions
-
- Conference Paper
- C3
- open access
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study
-
- Conference Paper
- C3
- open access
KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
-
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)
-
- Journal Article
- A1
- open access
Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial
-
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease
-
- Conference Paper
- C3
- open access
Intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for irresectable peritoneal metastases : a first in human phase I study
-
Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic : an international, multicenter, comparative cohort study
-
Retrospective analysis of mpMRI to predict complete pathologic response after neo-adjuvant chemotherapy for muscle invasive bladder cancer
-
- Journal Article
- A1
- open access
Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
-
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer : preliminary results
-
- Journal Article
- A1
- open access
Has the PROPHECY of AR-V7 been fulfilled?
-
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial
-
- Journal Article
- A1
- open access
AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
-
Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results
-
Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO) : results from a phase II multicenter study.
-
Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer : preliminary analysis of the PePiTA study
-
Treatment of ovarian cancer with intraperitoneal platinum : heating up the debate
-
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study
-
Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)
-
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.
-
Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer
-
Clinical utility study of confirms mdx for prostate cancer in a community urology practice
-
Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men
-
Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple negative breast cancer (TNBC) or colorectal cancer (CRC).
-
A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors
-
- Journal Article
- A1
- open access
Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al
-
Effects of molecular tumor board and different NGS panels implementation for the treatment of patients with cancer
-
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial
-
Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM)
-
High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib
-
Prognostic significance of number versus location of positive mesenteric nodes in node positive colon cancer
-
Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.
-
Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab
-
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC)
-
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types
-
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
-
Distrust in the end-of-life care provided to a parent and long-term negative outcomes among bereaved adolescents : a population-based survey study
-
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores
-
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors
-
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110
-
Ability of an epigenetic assay to identify anterior prostate tumors based on a negative 12-core biopsy
-
Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease
-
Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
-
Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma
-
Childhood acute lymphoblastic leukemia : progress through collaboration
-
Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk prediction of hepatocellular carcinoma in compensated cirrhosis
-
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP : first results of the EURAMOS-1 good respons randomized controlled trial
-
Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy : first results of the randomized trial SAKK 09/10
-
Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10
-
Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML : results from an international retrospective study by the International Berlin-Frankfurt-Münster study group
-
Collaborative efforts driving progress in pediatric acute myeloid leukemia
-
Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20⁺ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study
-
Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program
-
Identification of a predictive signature based on immunohistochemical (IHC), RNA-seq and epigenetic profiling of melanoma metastases for response to ipilimumab-based immunotherapy
-
Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer
-
Toxicities and doses of chemotherapy drugs in hyperthermic intraperitoneal chemotherapy (HIPEC)
-
2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers
-
Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study
-
A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors
-
Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal cancer (aCRC) : REGARD-C study
-
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial
-
Emergence of new ALK mutations at relapse of neuroblastoma
-
Epigenetic profiling of prostate cancer tissue to identify men with high-risk disease
-
A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies
-
Nomograms to predict prognosis in pseudomyxoma peritonei: a Peritoneal Surface Oncology Group International (PSOGI) multicenter study
-
DUO: a phase 3 trial of the PL3K-delta,gamma inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphorytic lymphoma
-
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): overall survival (OS) results of MM-003 after adjustment for Res crossover
-
Durable disease control with sunitinib and everolimus in well-differentiated neuroendocrine tumors of the pancreas with a high ki67 index
-
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
-
Type I and II endometrial cancers : have they different risk factors?
-
Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium: a Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique study
-
Assessment of the quality of the pathological evaluation of total mesorectal excision specimens : differences in evaluation between local pathologists and a review committee in the context of an improvement project
-
Trends in end-of-life decision making in patients with and without cancer
-
CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer
-
Prediction of risk for prostate cancer in histopathologically negative biopsies by multigene epigenetic assay
-
Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer
-
Serum mesothelin for diagnosing malignant pleural mesothelioma : an individual patient data meta-analysis
-
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study
-
Early- and long-term outcome data of patients with Pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
-
- Conference Paper
- C3
- open access
FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study
-
Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials
-
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition
-
End-of-life care and circumstances of death in patients dying as a result of cancer in Belgium and the Netherlands: a retrospective comparative study
-
Malignant peritoneal mesothelioma in a patient with Li-Fraumeni syndrome
-
An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC)
-
The prognostic significance of mucinous differentiation in colorectal cancer: a systematic review and meta-analysis
-
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
-
Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer
-
Which patients with cancer die at home?: a study of six European countries using death certificate data
-
Prognostic impact of gene expression-based classification for neuroblastoma
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study
-
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
-
Bresolin_2010_Gene exGene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia
-
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005
-
Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study
-
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
-
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
-
Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab
-
Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer
-
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
-
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicenter prospective phase II clinical study
-
Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) pooled safety results
-
EGFR and K-RAS gene status evaluation in anal canal squamous cell carcinoma
-
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
-
A Phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Gene expression differentiates liver metastases from isolated peritoneal metastases in colorectal cancer
-
Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers
-
Use of laparoscopy for rectal cancer: a word of caution
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
Intensity modulating and other radiation therapy devices for dose painting
-
Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma
-
Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma
-
End-of-life decisions among cancer patients compared with noncancer patients in Flanders, Belgium
-
Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage - Reply
-
Short-term treatment-related symptoms and quality of life: Results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study
-
Does downstaging in patients (pts) with IIIA-N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941
-
Progression-free survival rate as primary end point for phase II cancer clinical trials: Application to mesothelioma - The EORTC Lung Cancer Group
-
Survial data of 87 adenocarcinomas of the pancreas
-
An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC)
-
No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas
-
The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer
-
Predicting survival using health related quality of life scores in glioblastoma cancers : findings from an international phase III randomised controlled trial
-
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
-
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma
-
Use of radiolabeled bombesin in humans - Reply
-
Survival data of 87 adenocarcinomas of the pancreas
-
In vivo mapping of the effects of radiotherapy on neovascular permeability using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
-
Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas
-
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects
-
CPT-11 and mitomycin-C in heavily pre-treated patients with metastatic colorectal cancer: a belgian multicentre phase II study
-
Clinical implementation of intesity modulated arc therapy (IMAT) for rectal cancer
-
An randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreatic cancer
-
Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA
-
Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: a phase II study
-
Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer
-
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population : an international multicenter study
-
Predicting survival with health-related quality of life scores in locally advanced breast cancer : results from an international randomized controlled trial
-
Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3NO prostate cancer (PC)? (EORTC 22911)
-
Fas expression in pancreatic adenocarcinoma is related to prognosis
-
Limited influences of chemotherapy on healthy and metastatic liver parenchyma from colorectal cancer
-
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte
-
Receptor imaging in oncology by means of nuclear medicine: Current status
-
First experience with a new implantable gold marker for extracranial high precision radiotherapy
-
Clinical implementation of intensity modulated arc therapy (IMAT) for rectal cancer.
-
Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC)
-
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)
-
Adjuvant gemcitabine (GEM) and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter belgian phase II study
-
Raltitrexed/gemcitabine in patients with advanced biliary tract adenocarcinoma: a phase II study
-
Guidelines for the use of epoetin : have quality-of-life benefits been proven?
-
Quality assessment of genetic markers used for therapy stratification
-
- Journal Article
- A1
- open access
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975
-
Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography
-
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial.
-
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
-
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
-
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853.
-
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
-
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial.
-
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
-
Treatment of multifocal primary cutaneous B-cell lymphoma: A clinical follow-up study of 29 patients.
-
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia
-
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study.
-
CD30/KI-1 positive lymphoproliferative disorders of the skin - Clinicopatho-logic correlation and statistical analysis of 86 cases - a multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group.
-
OPTIMAL COMBINATION THERAPY WITH TROPISETRON IN 445 PATIENTS WITH INCOMPLETE CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.